^
    Back
    Association details:
    Biomarker:BRAF V600K
    Cancer:Melanoma
    Drug Class:PD1 inhibitor +
    CTLA4 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Immunother Cancer
    Title:

    Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

    Published date:
    01/22/2021
    Excerpt:
    We performed a single-center retrospective cohort analysis of patients who received anti-PD1±anti-CTLA4 ICI...In multivariable analyses, combination ICI was associated with longer OS in NRAS (HR 0.24, 95% CI 0.10 to 0.62, p=0.003, n=69) and BRAF V600E/K (HR 0.47, 95% CI 0.24 to 0.90, p=0.024, n=86) mutant melanoma but not BRAF/NRAS wild-type (n=94) melanoma.
    DOI:
    10.1136/jitc-2020-001642